ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3258

Different Perception of Disease Activity in Multimorbid Rheumatoid Arthritis Patients

Helga Radner1,2, Kazuki Yoshida1,3, Sara K. Tedeschi4, M Frits5, C Iannaccone6, N Shadick7, Michael Weinblatt1, Daniel Aletaha8, Josef S. Smolen9 and Daniel H. Solomon10, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Department of Epidemiology, Harvard School of Public Health, Boston, MA, 4Rheumatology, Brigham & Women's Hospital, Boston, MA, 5Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 7Division of Rheumatology, Immunology & Allergy, Brigham and Women's Hosp, Boston, MA, 8Rheumatology, Medical University Vienna, Vienna, Austria, 9Dept of Medicine 3, Division of Rheumatology, Medical Univ Vienna, Vienna, Austria, 10Rheumatology, Brigham and Women's Hospital, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Comorbidity, outcome measures and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 11, 2015

Title: Rheumatoid Arthritis - Clinical Aspects VII: Disease Activity and Updates in Measurement

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: The
patient rating of global rheumatoid arthritis (RA) disease activity (PtGA) is a key variable in composite measures of disease
activity as well as definition of remission (REM). In multimorbid RA patients
(RA-MM) the perception of RA disease activity as measured by the PtGA might be impacted by the burden of multiple diseases,
leading to higher levels of PtGA. In this study, we
aimed to quantify the difference in PtGA between
RA-MM and RA-only patients and to determine the factors contributing to this difference.

Methods: We compared mean
levels of PtGA between RA-MM and RA-only patients
followed in a longitudinal RA cohort at an academic medical center. Multimorbidity
was defined as having at least one chronic condition in addition to RA and
assessed by the counted multimorbidity index (cMMI ³ 2) [1]. The mean
difference in PtGA (ΔPtGA)
between RA-MM and a cohort of RA-only patients, matched on swollen and tender
joint count (SJC, TJC), evaluator global of disease activity, and disease
duration, was assessed. The unique contribution of specific components to the
explained variation of ΔPtGA in the matched
cohort was calculated as semi-partial R
2 in linear
regression models and summarized as the percentage of the total R2.

Results: Out of a total of 1,040
RA patients, 575 (55.5%) were multimorbid; RA-MM reported higher (worse) PtGA, with a positive linear relationship between number of
morbidities and PtGA (linear trend p<0.01). This
relationship remained significant after adjusting for disease activity, age and
disease duration (Figure 1).   In the matched cohort of 294 RA-MM
patients and 294 RA-only patients, the mean PtGA (in
mm) was significantly higher for RA-MM (30.5±24.3) versus RA-only patients
(25.6±22.9), with a mean difference of 4.9±26.7 (p<0.01, paired t-test).
Variables contributing to this difference were fatigue (18.2% of total R2),
pain (16.8% of total R2) and modified health assessment
questionnaire (mHAQ; 8.7% of total R2). Age,
gender and level of education were not significantly contributing to the
difference in PtGA between RA-MM and RA-only.

Conclusion: RA-MM patients had
higher levels of PtGA compared to RA-only patients.
The most relevant determinants of this difference in PtGA
between RA-MM and RA-only patients are differences in fatigue and pain.

Figure 1. This figure demonstrates higher
mean values of patient global of disease activity (PtGA)
in groups of patients with higher number of morbidities assessed by the counted
multimorbidity index (cMMI). Panel A
shows unadjusted analyses of variance (ANOVA) testing for linear trend
p<0.001. Panel B shows adjusted
estimated marginal means generated by a general linear model considering all
covariates set to the cohort’s mean (tender joint count= 7.9; swollen joint
count = 7.1; evaluator global = 32.2; Age = 56.8; Disease duration = 13.7years).


Disclosure: H. Radner, None; K. Yoshida, None; S. K. Tedeschi, None; M. Frits, None; C. Iannaccone, None; N. Shadick, Amgen, Questcor, Crescendo Biosciences, UCB, Bristol-Myers Squibb, 2; M. Weinblatt, Amgen, Abbvie, Bristol-Myers Squibb, Lilly, Novartis, Merck, Pfizer, Roche, Crescendo, Myriad Genetics, UCB, 5,Bristol-Myers Squibb, Myriad Genetics, UCB, 2; D. Aletaha, None; J. S. Smolen, Abbvie, Janssen, MSD, Pfizer, Roche, UCB, 2,Abbvie, Amgen, Astra-Zeneca, Astro, Celgene, Glaxo, ILTOO, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Novo-Nordisk, Pfizer, Roche, Samsung, Sanofi, UCB, 5; D. H. Solomon, None.

To cite this abstract in AMA style:

Radner H, Yoshida K, Tedeschi SK, Frits M, Iannaccone C, Shadick N, Weinblatt M, Aletaha D, Smolen JS, Solomon DH. Different Perception of Disease Activity in Multimorbid Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/different-perception-of-disease-activity-in-multimorbid-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/different-perception-of-disease-activity-in-multimorbid-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology